Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying long-term treatment options for patients with advanced solid tumors, including non-small cell lung cancer and colorectal cancer, who previously participated in studies involving adagrasib either alone or with other cancer therapies. This open-label continuation trial enrolls patients from ongoing parent studies to evaluate the ongoing effects and safety of these treatments. The trial is sponsored by Mirati Therapeutics Inc. and aims to provide insights into long-term treatment outcomes for these cancer types. Participants receive adagrasib and may also receive other cancer drugs such as pembrolizumab, cetuximab, pemetrexed, docetaxel, irinotecan, leucovorin, oxaliplatin, or fluorouracil. These drugs are given at specified doses on specified days within the trial. The study includes multiple experimental arms, reflecting different treatment combinations or sequences based on prior parent study participation. During the study, participants are monitored for adverse events, including serious side effects and events leading to treatment discontinuation or death, for up to 90 days after their last dose or if they stop the study early. Researchers track safety and tolerability through regular assessments. Participants remain under observation for the duration of their involvement, which extends until the study completion date in February 2028.
Actively Recruiting
Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.
Actively Recruiting
This research aims to evaluate LN-145, an autologous tumor-infiltrating lymphocyte TIL therapy, in patients with metastatic non-small-cell lung cancer NSCLC. This phase 2, open-label, multi-cohort, non-randomized study involves patients with metastatic NSCLC, including those with varying PD-L1 tumor expression levels. The study excludes patients with certain genetic mutations and focuses on those with disease progression after prior therapies. The primary purpose is to assess treatment response and safety over time. Participants receive LN-145, which is produced by collecting a tumor sample to expand TILs outside the body. Before the infusion of LN-145, patients undergo a non-myeloablative lymphodepleting chemotherapy regimen including cyclophosphamide and fludarabine. After LN-145 infusion, patients are given IL-2 to support immune response. The study includes several cohorts based on tumor PD-L1 status, prior treatments, and other factors, with specific eligibility and treatment pathways for each. Throughout the study, participants are monitored for objective response rate and other outcomes up to 60 months. Assessments include disease progression evaluation, adverse event tracking, and biopsies. The study spans from screening through treatment and extended follow-up to evaluate long-term effects. Participants must meet performance and organ function criteria and agree to use effective birth control during and after treatment.
Actively Recruiting
This research aims to enhance self-management skills for adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. It evaluates a mobile health m-health solution personalized by diabetologists and integrated with electronic patient records, comparing its use to usual diabetes care. The main goal is to measure changes in glycated haemoglobin HbA1c levels over a 12-month period to assess the effectiveness of this digital support. Participants will be randomly assigned to either a treated group using the m-health solution or a control group receiving regular care. The m-health system includes mobile apps for tracking health data such as blood sugar, physical activity, and diet, sending alerts and motivational messages, allowing communication with healthcare professionals, and providing access to educational materials. Healthcare providers will monitor patient data through an integrated electronic platform. The treatment lasts 12 months with evaluations at baseline, 4, 8, and 12 months. During the study, participants will engage in clinical assessments and complete validated questionnaires covering disease severity, medication adherence, lifestyle habits, self-efficacy, and quality of life. Data will be collected from self-reports, clinical visits, and the m-health app. Researchers will also explore patients experience and satisfaction with the m-health solution and assess its cost-effectiveness. No extra visits or lab tests beyond routine care are required.
Actively Recruiting
Researchers are evaluating the EuroHeart program, an observational and prospective multicenter initiative designed to improve quality of care for patients with common cardiovascular diseases such as Acute Coronary Syndrome ACS, heart failure, and atrial fibrillation. EuroHeart collects standardized and harmonized patient data to support continuous quality improvement by monitoring adherence to quality indicators defined by the European Society of Cardiology ESC. The program aims to understand how well proven treatments are applied in everyday clinical practice. The study involves continuous data collection from consecutive patients hospitalized or treated for these cardiovascular conditions. Participants enter a 12-month follow-up period during which clinical events and health status data are gathered. This registry specifically evaluates adherence to ESC quality indicators in Italian clinical practice, including measures such as time to reperfusion and prescription of recommended medications at discharge. Participants will be monitored through regular collection of clinical data over the 12 months following enrollment. Researchers will assess adherence to multiple ESC quality indicators related to treatment and management of STEMI and NSTEMI patients, including evaluations of left ventricular function, lipid levels, and use of dual antiplatelet therapy and other medications. The study also tracks cardiovascular and non-cardiovascular events during follow-up to support quality improvement efforts. Participation involves consent and data collection without experimental treatments.
Actively Recruiting
Researchers are conducting the PANThEON trial, a randomized, open-label, multicenter phase III study, to compare two chemotherapy approaches in patients with advanced pancreatic adenocarcinoma that cannot be surgically removed or has spread. The study aims to evaluate overall survival by comparing continuing modified FOLFIRINOX versus switching to gemcitabine plus nab-paclitaxel after initial induction chemotherapy. Eligible patients have stable or responding disease after about 3 months of initial mFOLFIRINOX treatment. During the study, all participants first receive induction chemotherapy with mFOLFIRINOX for up to 14 weeks, consisting of about six cycles every two weeks. Patients who show no disease progression are then randomly assigned to either continue mFOLFIRINOX Arm A or switch to gemcitabine plus nab-paclitaxel Arm B. Arm A treatments include oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil given every two weeks until progression or unacceptable side effects. Arm B treatments involve gemcitabine and nab-paclitaxel administered on days 1, 8, and 15 of each 28-day cycle until progression or toxicity. Participants will have tumor imaging before and after induction chemotherapy to assess response. Throughout the trial, researchers will monitor overall survival up to 48 months, along with other outcomes like progression-free survival, treatment failure time, response rates, quality of life, and treatment toxicity. Safety and disease status will be regularly assessed, and participants may continue treatment or withdraw as needed. The trial is expected to last until 2030, with ongoing follow-up for health status and outcomes.
Actively Recruiting
Researchers are evaluating the effect of adding gemtuzumab ozogamicin to standard chemotherapy for adults aged 18 to 60 with newly diagnosed favorable or intermediate-risk acute myeloid leukemia AML. This phase 3 study aims to reduce minimal residual disease MRD levels before transplantation and assess whether MRD-driven post-remission therapy can improve anti-leukemic outcomes. The study excludes patients with certain genetic markers or prior treatments to focus on a specific AML subgroup. Participants receive induction treatment with gemtuzumab, daunorubicin, and cytosine arabinoside, followed by consolidation therapy with adjusted doses of these drugs. After consolidation, patients undergo either autologous or allogeneic stem cell transplantation based on their MRD level. This MRD-guided approach helps tailor the intensity of post-remission therapy. Throughout the study, participants undergo MRD assessments to measure treatment activity, with the primary outcome being MRD negativity two months after starting therapy. Researchers also monitor kidney and liver function, heart health, and overall compliance with study procedures. The study involves regular clinical observations and assessments to evaluate the effectiveness of the combined treatment and its impact on MRD levels over time.
Actively Recruiting
This research focuses on adult patients newly diagnosed with myelodysplastic syndrome MDS, aiming to collect epidemiological data across Italy. The study seeks to develop a network of regional registries that use a standardized electronic case report form to store and process anonymous patient data. This network also aims to integrate Italian data with international MDS registries for broader analysis. Participants contribute data to the registry without receiving specific treatments through this study. The data collected will include detailed patient information related to their MDS diagnosis and progression over time. The study spans several years, allowing long-term observation and aggregation of epidemiological data. Throughout the study, researchers will review important outcomes such as the incidence and prevalence of MDS, overall response rates, survival rates, progression to acute myeloid leukemia, and progression-free survival over a six-year period. Participants provide data over time, and the registry helps monitor these outcomes to better understand the disease and its impact.
1-10 of 20
1